The following is a summary of the Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Longeveron reported a revenue of $1.8 million for the first nine months of 2024, marking an increase of 177% compared to the same period in 2023.

• Total operating expenses for the first nine months decreased by 14% year-over-year.

• The company reported a net loss of $11.9 million for the nine months ended September 30, 2024, a 22% decrease compared to the previous year.

Business Progress:

• Longeveron is advancing its HLHS program with its ongoing Phase 2b study, ELPIS II, achieving over 80% enrollment.

• The company anticipates completing the enrollment by early next year and expects to initiate a rolling submission of a BLA to the FDA in 2026 if ELPIS II results are positive.

• Longeveron's Alzheimer's disease program, featuring Lomecel-B, received RMAT and Fast-Track designation from the FDA based on promising Phase 2a clinical trial results.

Opportunities:

• Longeveron is capitalizing on the regenerative medicine advanced therapy (RMAT) designation and Fast-Track designation for Lomecel-B in Alzheimer's disease treatment.

Risks:

• Challenges in Alzheimer's disease treatment development are acknowledged, yet Longeveron remains encouraged by the results seen with Lomecel-B.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.